Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended June 30: Earnings Summary

Acadia Pharmaceuticals

04/08/2026 22:37

ACADIA Pharmaceuticals Inc ACAD.OQ reported quarterly adjusted earnings of 18 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 16 cents.  The mean expectation of twenty one analysts for the quarter was for earnings of 6 cents per share. Wall Street expected results to range from -11 cents to 20 cents per share.
Revenue rose 16.4% to $307.96 million from a year ago; analysts expected $295.86 million. 
ACADIA Pharmaceuticals Inc's reported EPS for the quarter was 18 cents​.
The company reported quarterly net income of $31.5 million.
ACADIA Pharmaceuticals Inc shares had risen by 1.2% this quarter and lost 4.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 52.3% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $35.00, about 26.8% above its last closing price of $25.61
This summary was machine generated from LSEG data August 4 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.06
0.18
Beat
Mar. 31 2026 
0.06
0.02
Missed
Dec. 31 2025 
0.14
1.60
Beat
Sep. 30 2025 
0.15
0.42
Beat